Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$107.26 USD

107.26
8,540,923

+3.34 (3.21%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $107.01 -0.25 (-0.23%) 4:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Analyst Reports for SAP, Abbott Laboratories & Citigroup

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook

by Zacks Equity Research

Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.

Jobless Claims Increased More Than Expected

by Zacks Equity Research

Jobless Claims Increased More Than Expected

Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.

Mark Vickery headshot

Jobless Claims Rise Again, D.R. Horton Posts Strong Quarter

by Mark Vickery

+1.867 million longer-term jobless claims is the highest single-week figure we've seen since November of 2021.

Compared to Estimates, Abbott (ABT) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Abbott (ABT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 0.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Moumi Mondal headshot

Pre Q3 Earnings: Is Hologic (HOLX) Stock a Portfolio Must-Have?

by Moumi Mondal

Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.

Mark Vickery headshot

Dow Closes at New High as Q2 Earnings Season Heats Up

by Mark Vickery

Earnings season only picks up steam in the weeks to come.

Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release

by Zacks Equity Research

Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.

Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $101.64, marking a -0.47% move from the previous day.

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?

by Debanjana Dey

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs

by Zacks Equity Research

Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.

Urmimala Biswas headshot

Medtronic Loses 5% in a Month: What's Next for MDT Investors?

by Urmimala Biswas

Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

by Zacks Equity Research

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abbott (ABT) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the closing of the recent trading day, Abbott (ABT) stood at $105.49, denoting a +0.18% change from the preceding trading day.

Abbott's (ABT) EPD Expansion Continues Despite FX Headwind

by Zacks Equity Research

Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.

The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine

by Zacks Equity Research

Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine are included in this Analyst Blog.

Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Mark Vickery headshot

Top Analyst Reports for Abbott, BP & Gilead

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Smith-Midland Corporation (SMID) and Crimson Wine Group, Ltd. (CWGL).

Aurora Cannabis Inc. (ACB) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of 161.11% and 2.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Patterson Cos. (PDCO) Misses Q4 Earnings Estimates

by Zacks Equity Research

Patterson Cos. (PDCO) delivered earnings and revenue surprises of -1.20% and 0.02%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

Abbott (ABT) concluded the recent trading session at $103.45, signifying a -0.22% move from its prior day's close.